跳转至内容
Merck

PHR1377

Supelco

别嘌醇

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

别嘌醇, 1H-吡唑并 (3,4-d) 嘧啶-4-醇, 4-羟基吡唑并 (3,4-d) 嘧啶, 4-羟基吡唑并 [3,4-d] 嘧啶, HPP

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C5H4N4O
CAS号:
分子量:
136.11
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material
pharmaceutical secondary standard

品質等級

agency

traceable to BP 870
traceable to Ph. Eur. A0350000
traceable to USP 1013002

API 家族

allopurinol

CofA

current certificate can be downloaded

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

>300 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-30°C

SMILES 字串

O=C1NC=Nc2[nH]ncc12

InChI

1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)

InChI 密鑰

OFCNXPDARWKPPY-UHFFFAOYSA-N

基因資訊

human ... XDH(7498)

正在寻找类似产品? 访问 产品对比指南

一般說明

用于质量控制的药物二级标准品,为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
别嘌醇是一种用于治疗慢性痛风或高尿酸血症的药物。它的作用方式涉及抑制黄嘌呤氧化酶,黄嘌呤氧化酶是催化次黄嘌呤羟基化为黄嘌呤和黄嘌呤羟基化为尿酸的重要酶。

應用

别嘌醇可用作药物标准品,通过色谱技术测定药物制剂中的分析物。
这些二级标准品是合格的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。

生化/生理作用

黄嘌呤氧化酶和初始嘧啶生物合成的抑制剂。治疗高尿酸血症和痛风的经典药物。

分析報告

这些二级标准品可追溯至USP、EP(PhEur)和BP一级标准品。

其他說明

该认证标准物质(CRM)根据ISO 17034ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在检验报告上找到。

腳註

想要查看本品的检验报告示例,请在下框中输入LRAA1633。这只是一个示例证书,可能与您收到的批次不符。

相關產品

产品编号
说明
价格

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Skin Sens. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Spectrophotometric determination of allopurinol drug in tablets: Spectroscopic characterization of the solid CT complexes.
Refat MS, et al.
Bull. Korean Chem. Soc., 31(6), 1535-1542 (2010)
Spectrophotometric determination of Allopurinol in tablet formulation.
Khayoon WShakir, et al.
Journal of Physical Science, 19(2), 23-30 (2008)
Tsen-Fang Tsai et al.
American journal of clinical dermatology, 11(4), 225-232 (2010-06-01)
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has
Stephanie Peglow et al.
Journal of hepato-biliary-pancreatic sciences, 18(2), 137-146 (2010-09-30)
Allopurinol was first introduced, in 1963, as a xanthine oxidase inhibitor when it was investigated for concomitant use with cancer chemotherapy drugs. Today it is used in gout and hyperuricemia. Due to its additive benefit in preventing oxidative damage, attention
Ratchadaporn Somkrua et al.
BMC medical genetics, 12, 118-118 (2011-09-13)
Despite some studies suggesting a possible association between human leukocyte antigen, HLA-B*5801 and allopurinol induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the evidence of association and its magnitude remain inconclusive. This study aims to systematically review and meta-analyze

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门